Welcome to our dedicated page for AEMETIS SEC filings (Ticker: AMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AEMETIS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AEMETIS's regulatory disclosures and financial reporting.
Aemetis, Inc. reported Q2 2026 results with revenue of $62.7 million, up from $52.2 million a year earlier, and a narrowed net loss of $9.4 million versus $23.4 million. Gross profit turned positive at $13.5 million and operating income reached $5.8 million, driven by stronger California ethanol and renewable natural gas activity and recognition of Section 45Z production tax credits within revenue.
For the first half of 2026, revenue was $117.3 million and net loss was $31.1 million. Interest and related costs remained heavy at $31.2 million year‑to‑date, reflecting substantial borrowings. Total debt was $415.9 million, with $354.2 million classified as current, while total assets were $289.2 million and stockholders’ deficit was $322.1 million. Cash, cash equivalents, and restricted cash were $3.5 million, and operating activities used $12.4 million of cash in the first half.
Management discloses substantial doubt about the company’s ability to continue as a going concern over the next twelve months, citing high leverage, dependence on its senior lender, near‑term maturities, and required redemption or refinancing of $130.2 million of Series A preferred units. Plans to address liquidity include monetizing Section 45Z credits, optimizing plant operations, expanding dairy RNG projects, continuing equity issuance, and pursuing refinancings and project‑level financing.
Aemetis reported significantly improved Q2 2026 results, with revenue of $62.7 million, including $8.6 million of Section 45Z production tax credits, up 20% year over year. Gross profit reached $13.5 million and operating income was $5.8 million, reversing losses in the prior-year quarter.
Performance was driven by higher volumes and prices in the California Ethanol segment, lower delivered corn costs, and 38% growth in Dairy Renewable Natural Gas volumes, supported by seven approved LCFS provisional pathways. Adjusted EBITDA turned positive at $9.7 million, while the India biodiesel business operated at low nameplate utilization.
Despite operating improvements, Aemetis posted a Q2 net loss of $9.4 million and ended June 30, 2026 with $1.0 million in cash, about $415.0 million of current liabilities, and a stockholders' deficit of roughly $322.1 million. The company is pursuing multiple financing initiatives, including Keyes plant refinancing, Dairy RNG funding, and a potential IPO of its India subsidiary.
BlackRock, Inc. reports beneficial ownership of common stock of Aemetis Inc. on a Schedule 13G. BlackRock and certain of its subsidiaries and affiliates collectively beneficially own 3,970,397 shares of Aemetis common stock, representing 5.6% of the class.
BlackRock has sole voting power over 3,920,545 shares and sole dispositive power over all 3,970,397 shares, with no shared voting or dispositive power. Various underlying clients and investors have rights to dividends or sale proceeds, but no single person has more than five percent of Aemetis’ outstanding common shares.
Aemetis, Inc. director Simon Timothy Alan sold shares in the company. He completed an open-market sale of 10,000 shares of Common Stock at a weighted average price of about $2.05 per share. After this transaction, he directly holds 42,632 shares of Aemetis Common Stock.
The reported sale price reflects a weighted average of multiple trades within a range of $2.04 to $2.06 per share, as noted in the footnote. The filing does not show any related option exercises or derivative positions, indicating this was a straightforward common stock sale.
AMTX reported a proposed sale of Common Stock via Form 144. The notice lists transactions tied to RSU vesting events dated 06/10/2026, with reported lots of 6,441, 10,000 and 2,559 shares and a broker identified as Raymond James & Associates. The filing indicates cash sale of vested common shares on 06/10/2026.
Aemetis, Inc. held its Annual Meeting of Stockholders on May 20, 2026. Stockholders voted on the election of one director and the ratification of the company’s independent auditor.
For the board election, Lydia I. Beebe received 18,110,640 votes for, 627,847 withheld, and 19,501,347 broker non-votes. She was elected as a Class II director to serve until the 2029 annual meeting and until a successor is elected and qualified.
Stockholders also voted on the ratification of the company’s independent registered public accounting firm. KPMG LLP received 37,777,860 votes for, 85,378 against, and 376,596 abstentions, with no broker non-votes, and was ratified as auditor for the fiscal year ending December 31, 2026.
Aemetis, Inc. reported first‑quarter 2026 revenue of $54.6 million, up from $42.9 million, driven by strong growth in India biodiesel and California renewable natural gas plus new Section 45Z production tax credits.
Gross profit improved to $2.8 million from a $5.1 million loss, but the company still posted a net loss of $21.7 million and used $10.6 million of cash in operating activities. Total debt reached $404.7 million, with $342.6 million classified as current and several facilities due on demand. Management discloses substantial doubt about the company’s ability to continue as a going concern absent refinancing, additional financing, and continued cooperation from its senior lender.
Aemetis, Inc. reported first quarter 2026 results showing strong top-line growth but continued losses. Revenue rose 27% year over year to $54.6 million, driven by contributions from California Ethanol, Dairy Renewable Natural Gas (RNG), and India Biodiesel.
The company generated $2.8 million of gross profit, reversing a gross loss in the prior-year quarter, helped by Section 45Z Production Tax Credits and improved Dairy RNG performance. Operating loss narrowed to $6.3 million, and net loss improved to $21.7 million, while Adjusted EBITDA improved to negative $1.3 million from negative $10.7 million.
Dairy RNG volumes increased 55% to 110,000 MMBtu, and India Biodiesel revenue reached $10.5 million with resumed tender orders. The company ended the quarter with $4.8 million in cash and continues to invest in low-carbon projects and multi-track financing initiatives, including work toward an IPO of its India subsidiary.
Aemetis, Inc. is calling its 2026 Annual Meeting of Stockholders for May 20, 2026 in Palo Alto. Stockholders of record at the close of business on March 26, 2026, when 68,145,588 common shares were outstanding, may vote.
Investors will vote on electing Lydia I. Beebe to a new three-year term as a Class II director through 2029 and on ratifying KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, replacing RSM US LLP. The proxy also outlines board structure, director and executive pay, equity plans, severance protections, and related-party employment of family members of the CEO.
Waltz Todd reported acquisition or exercise transactions in this Form 4 filing.
Aemetis, Inc. Executive Vice President and CFO Todd Waltz received a compensation grant of options to buy 200,000 shares of common stock at $2.64 per share. These options begin vesting after the grant date, with 1/12 of the option shares vesting every three months.
The options are exercisable until March 19, 2036 and relate to 200,000 underlying shares of common stock. Following this award, the filing shows Waltz holding a total of 1,305,701 derivative securities, indicating a sizeable ongoing equity-based stake aligned with company performance.